US Patent No: 8,206,706

Number of patents in Portfolio can not be more than 2000

Method for enhancing or inhibiting insulin-like growth factor-I

ALSO PUBLISHED AS: 20090226452

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLCHAPEL HILL, NC884

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Clemmons, David R Chapel Hill, NC 15 13
Maile, Laura A Chapel Hill, NC 13 9

Cited Art Landscape

Patent Info (Count) # Cites Year
 
APPLIED MOLECULAR EVOLUTION, INC. (3)
6,531,580 Anti-.alpha.v.beta.3 recombinant human antibodies and nucleic acids encoding same 13 1999
7,371,382 Methods of inhibiting .alpha..sub.v.beta..sub.3-mediated binding with .alpha..sub.v.beta..sub.3-specific antibodies 4 2002
7,422,744 Methods of treating cancer with alphavbeta3-specific antibodies 4 2003
 
IXSYS, INCORPORATED (2)
6,590,079 Anti-.alpha.v.beta.3 recombinant human antibodies, nucleic acids encoding same 7 1997
6,596,850 Anti-.alpha.v3.beta.3 recombinant human antibodies, nucleic acids encoding same 8 1998
 
The Scripps Research Institute (2)
5,753,230 Methods and compositions useful for inhibition of angiogenesis 69 1994
7,354,586 Methods of treating arthritis and diabetic retinopathy with .alpha..sub.v.beta..sub.3-specific antibodies 4 2004
 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2)
7,723,483 Method for enhancing or inhibiting insulin-like growth factor-I 2 2005
2009/0280,127 MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I 1 2009
 
Genentech, Inc. (1)
5,578,704 Antibody to osteoclast alphavbeta3 ntegrin 25 1994
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
6,887,473 Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody 8 1998
 
Research Foundation for the State University of N.Y. (1)
5,336,618 Fibrinogen blocking monoclonal antibody 8 1988

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 26, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 26, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 26, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00